OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Titration of HCTZ to 50 mg Daily in Individuals With Stage 2 Systolic Hypertension Pretreated With an Angiotensin Receptor Blocker
Joseph L. Izzo, Joel M. Neutel, T SILFANI, et al.
Journal of Clinical Hypertension (2007) Vol. 9, Iss. 1, pp. 45-48
Open Access | Times Cited: 15
Joseph L. Izzo, Joel M. Neutel, T SILFANI, et al.
Journal of Clinical Hypertension (2007) Vol. 9, Iss. 1, pp. 45-48
Open Access | Times Cited: 15
Showing 15 citing articles:
Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension
David H.G. Smith
Drugs (2008) Vol. 68, Iss. 9, pp. 1207-1225
Closed Access | Times Cited: 72
David H.G. Smith
Drugs (2008) Vol. 68, Iss. 9, pp. 1207-1225
Closed Access | Times Cited: 72
Drug Therapy for Resistant Hypertension: Simplifying the Approach
Samuel J. Mann
Journal of Clinical Hypertension (2010) Vol. 13, Iss. 2, pp. 120-130
Open Access | Times Cited: 46
Samuel J. Mann
Journal of Clinical Hypertension (2010) Vol. 13, Iss. 2, pp. 120-130
Open Access | Times Cited: 46
Adverse effect profile of trichlormethiazide: a retrospective observational study
Yasuo Takahashi, Yayoi Nishida, Tomohiro Nakayama, et al.
Cardiovascular Diabetology (2011) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Yasuo Takahashi, Yayoi Nishida, Tomohiro Nakayama, et al.
Cardiovascular Diabetology (2011) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Treating Systolic Hypertension in the Very Elderly With Valsartan-Hydrochlorothiazide vs Either Monotherapy: ValVET Primary Results
Joseph L. Izzo, Howard Weintraub, Daniel Duprez, et al.
Journal of Clinical Hypertension (2011) Vol. 13, Iss. 10, pp. 722-730
Open Access | Times Cited: 16
Joseph L. Izzo, Howard Weintraub, Daniel Duprez, et al.
Journal of Clinical Hypertension (2011) Vol. 13, Iss. 10, pp. 722-730
Open Access | Times Cited: 16
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension
Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy (2007) Vol. 9, Iss. 1, pp. 129-136
Closed Access | Times Cited: 13
Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy (2007) Vol. 9, Iss. 1, pp. 129-136
Closed Access | Times Cited: 13
Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension
Yves Lacourcière, Luc Poirier, Jean Lefèbvre, et al.
Canadian Journal of Cardiology (2010) Vol. 26, Iss. 8, pp. e313-e319
Open Access | Times Cited: 12
Yves Lacourcière, Luc Poirier, Jean Lefèbvre, et al.
Canadian Journal of Cardiology (2010) Vol. 26, Iss. 8, pp. e313-e319
Open Access | Times Cited: 12
Influence of Age and Race on 24‐Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice
Joseph L. Izzo, Yan Jia, Dion Zappe
Journal of Clinical Hypertension (2016) Vol. 19, Iss. 2, pp. 143-150
Open Access | Times Cited: 8
Joseph L. Izzo, Yan Jia, Dion Zappe
Journal of Clinical Hypertension (2016) Vol. 19, Iss. 2, pp. 143-150
Open Access | Times Cited: 8
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide
Henry Punzi
Expert Review of Cardiovascular Therapy (2009) Vol. 7, Iss. 3, pp. 229-239
Closed Access | Times Cited: 9
Henry Punzi
Expert Review of Cardiovascular Therapy (2009) Vol. 7, Iss. 3, pp. 229-239
Closed Access | Times Cited: 9
Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide
Lars Christian Rump, Lorenz Sellin
Expert Opinion on Pharmacotherapy (2010) Vol. 11, Iss. 13, pp. 2231-2242
Closed Access | Times Cited: 8
Lars Christian Rump, Lorenz Sellin
Expert Opinion on Pharmacotherapy (2010) Vol. 11, Iss. 13, pp. 2231-2242
Closed Access | Times Cited: 8
Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
Peter Bramlage, Claudia Zemmrich, Ketelhut, et al.
Vascular Health and Risk Management (2013), pp. 475-475
Open Access | Times Cited: 7
Peter Bramlage, Claudia Zemmrich, Ketelhut, et al.
Vascular Health and Risk Management (2013), pp. 475-475
Open Access | Times Cited: 7
Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update
Steven G. Chrysant, Billy Dimas, Mohammad Shiraz
Journal of Human Hypertension (2007) Vol. 21, Iss. 9, pp. 699-708
Closed Access | Times Cited: 6
Steven G. Chrysant, Billy Dimas, Mohammad Shiraz
Journal of Human Hypertension (2007) Vol. 21, Iss. 9, pp. 699-708
Closed Access | Times Cited: 6
New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan
Vivencio Barrios, Carlos Escobar, Rocío Echarri, et al.
Hot Topics in Hypertension (2009)
Closed Access | Times Cited: 5
Vivencio Barrios, Carlos Escobar, Rocío Echarri, et al.
Hot Topics in Hypertension (2009)
Closed Access | Times Cited: 5
Olmesartan Medoxomil
Guıdo Grassı, Giuseppe Mancia
High Blood Pressure & Cardiovascular Prevention (2010) Vol. 17, Iss. 1, pp. 1-14
Closed Access | Times Cited: 3
Guıdo Grassı, Giuseppe Mancia
High Blood Pressure & Cardiovascular Prevention (2010) Vol. 17, Iss. 1, pp. 1-14
Closed Access | Times Cited: 3
Olmesartan medoxomil-based therapy for the management of hypertension
Mark Greathouse
Expert Review of Clinical Pharmacology (2008) Vol. 1, Iss. 5, pp. 593-604
Closed Access | Times Cited: 3
Mark Greathouse
Expert Review of Clinical Pharmacology (2008) Vol. 1, Iss. 5, pp. 593-604
Closed Access | Times Cited: 3
